RxDoctor Payments Data

Rakesh Patel, MD

Internal Medicine · Livonia, MINPI 1841257946

Payments from drug & device makers

$4,486in general payments, 2019–2025

Across 168 payments — averaging $26.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bioventus LLC$1K
  • Amgen$420
  • Bayer$354
  • Novo Nordisk$335
  • GSK$268
  • AstraZeneca$258
  • plus $2K from 25 others

What the payments were for

  • Consulting fees$1503%
  • Travel & lodging$1,14125%
  • Food & beverage$3,19571%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,486 in reported general payments places this provider in the 85th percentile of 4,567 internal medicine providers in Michigan.

See all internal medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$33,436
Medicare patients
62
Services billed
681

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban75$89,555
RybelsusSemaglutide22$32,725
XareltoRivaroxaban17$26,659
JanuviaSitagliptin Phosphate19$22,779
OzempicSemaglutide14$13,809
FarxigaDapagliflozin Propanediol13$9,348
InvokanaCanagliflozin12$6,576
Atorvastatin Calcium287$3,543
Lantus SolostarInsulin Glargine,hum.Rec.Anlog19$2,424
Losartan Potassium123$1,849
Omeprazole124$1,843
Trazodone Hcl20$1,842
Metoprolol Succinate84$1,793
Simvastatin158$1,763
Humalog Kwikpen U-100Insulin Lispro13$1,639

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$147$89,55575 claims
Novo NordiskRybelsus, Ozempic$335$46,53436 claims
Johnson & JohnsonXarelto, Invokana$91$33,23529 claims
MerckJanuvia$41$22,77919 claims
AstraZenecaFarxiga$258$9,34813 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,567 internal medicine providers in Michigan.

Other internal medicine in Livonia

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →